Discusses HOPE-3 Phase III Trial Results and Regulatory Path for Duchenne Muscular Dystrophy Therapy December 17, ...

In this article, we examine ongoing challenges shaping target-based drug discovery and highlight how new technologies and interdisciplinary approaches are helping to address them.

This paper presents an important advance in genetically encoded voltage imaging of the developing zebrafish spinal cord in vivo, capturing voltage dynamics in neuronal populations, single cells, and ...

Vor Biopharma has done well to continue to advance its very own global phase 3 study using its dual BAFF/APRIL inhibitor ...

Amphix Bio today announced the initial closing of a $12.5 million seed financing round to advance its lead therapeutic candidates toward human clinical trials and expand its pipeline to target ...

John Johnson, current board member, appointed to chairman of the boardMichael Kauffman, M.D., Ph.D., lead director since 2016, appointed to president of developmentCommercial launch progresses as RAMP ...

BioMarin Pharmaceutical Inc. and Amicus Therapeutics announced today that BioMarin has entered into a definitive agreement to acquire Amicus for $14.50 per share in an all-cash transaction for a total ...

BioMarin to Gain Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease, Adding Two Marketed, High-Growth Products with ...

While “staffing your company” is imperative and often emphasized, many commanders centralize critical information, leading to ...

The Cheyenne Street Railway Trolley offers narrated tours past historic sites, bringing the city’s colorful past to life. Holliday Park houses the Big Boy Steam Engine, the world’s largest steam ...

What keeps our cells the right size? Scientists have long puzzled over this fundamental question, since cells that are too ...

Imagine if our bodies could grow new organs throughout our entire lives. Plants do this constantly, thanks to tiny, powerful ...